SECOND SIGHT MEDICAL PRODUCT (EYES) Stock Price & Overview
NASDAQ:EYES • US81362J3086
Current stock price
The current stock price of EYES is 4.14 USD. Today EYES is down by -5.05%. In the past month the price decreased by -23.33%. In the past year, price decreased by -63.1%.
EYES Key Statistics
- Market Cap
- 54.384M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.69
- Dividend Yield
- N/A
EYES Stock Performance
EYES Stock Chart
EYES Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to EYES. When comparing the yearly performance of all stocks, EYES is a bad performer in the overall market: 93.97% of all stocks are doing better.
EYES Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYES. While EYES has a great health rating, there are worries on its profitability.
EYES Earnings
EYES Forecast & Estimates
For the next year, analysts expect an EPS growth of 96.18% and a revenue growth 35.73% for EYES
EYES Groups
Sector & Classification
EYES Financial Highlights
Over the last trailing twelve months EYES reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -42.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.82% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
EYES Ownership
EYES Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.91 | 178.754B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.23 | 160.562B | ||
| SYK | STRYKER CORP | 21.92 | 126.877B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.96 | 93.218B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.9 | 47.074B | ||
| IDXX | IDEXX LABORATORIES INC | 38.42 | 45.348B | ||
| BDX | BECTON DICKINSON AND CO | 11.33 | 43.995B | ||
| RMD | RESMED INC | 18.25 | 32.645B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.61 | 32.062B | ||
| DXCM | DEXCOM INC | 24.47 | 23.946B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.72 | 17.783B | ||
| HOLX | HOLOGIC INC | 15.41 | 16.888B | ||
| PODD | INSULET CORP | 31.6 | 14.383B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EYES
Company Profile
Second Sight Medical Products Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Sylmar, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The firm manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). The company is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
Company Info
IPO: 2014-11-19
SECOND SIGHT MEDICAL PRODUCT
12744 San Fernando Road, Bldg. 3
Sylmar CALIFORNIA 91342 US
CEO: Matthew Pfeffer
Employees: 15
Phone: 18188335000.0
SECOND SIGHT MEDICAL PRODUCT / EYES FAQ
Can you describe the business of SECOND SIGHT MEDICAL PRODUCT?
Second Sight Medical Products Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Sylmar, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The firm manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). The company is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
What is the current price of EYES stock?
The current stock price of EYES is 4.14 USD. The price decreased by -5.05% in the last trading session.
Does SECOND SIGHT MEDICAL PRODUCT pay dividends?
EYES does not pay a dividend.
How is the ChartMill rating for SECOND SIGHT MEDICAL PRODUCT?
EYES has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Should I buy EYES stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EYES.
What is the ownership structure of SECOND SIGHT MEDICAL PRODUCT (EYES)?
You can find the ownership structure of SECOND SIGHT MEDICAL PRODUCT (EYES) on the Ownership tab.